Sugi Predict

Sugi Predict / Compounds / SCHEMBL239690

SCHEMBL239690

SCHEMBL239690

c1ccc(Nc2nc3ccccc3[nH]2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.75
▸ KMT2A Q03164 2/20 0.75
▸ AKR1C3 P42330 1/20 0.66
▸ RAB9A P51151 6/20 0.60
▸ SMN1; SMN2 Q16637 5/20 0.60
▸ NPC1 O15118 5/20 0.60
▸ ALOX15 P16050 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ GAA P10253 1/20 0.60
▸ PYGM P11217 1/20 0.60
▸ HPGD P15428 1/20 0.60
▸ DDX3X O00571 1/20 0.58
▸ PDE10A Q9Y233 1/20 0.58
▸ MAPT P10636 2/20 0.58
▸ RIPK1 Q13546 1/20 0.57
▸ TP53 P04637 2/20 0.57
▸ CYP26A1 O43174 1/20 0.57
▸ LMNA P02545 2/20 0.55
▸ CYP1A2 P05177 1/20 0.55
▸ NPSR1 Q6W5P4 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30020996 1.00 MEN1 (0.75) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL28050241 0.88 RAB9A (0.68) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL1163606 0.87 MEN1 (0.69) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL757788 0.87 MEN1 (0.69) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL6037544 0.86 MEN1 (0.71) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL20685416 0.86 MEN1 (1.00) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL1996591 0.86 MEN1 (0.71) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL6037541 0.86 MEN1 (0.71) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL1163897 0.86 MEN1 (0.71) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2
SCHEMBL14881698 0.86 MEN1 (0.71) MEN1KMT2AAKR1C3RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 613 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3554505-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2019-10-23 — — EP claimed
WO-2018107226-A1 METHODS OF TREATING OCULAR DISORDERS Beta Therapeutics Pty. Ltd. (AU) 2018-06-21 — — WO claimed
CN-102942562-B Benzimidazole derivative, and preparation method and application thereof Tianjin Sphinx Medicine R&D Co., Ltd. (CN) 2014-10-01 — — CN claimed
US-8076072-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-12-13 — — US claimed
US-8026057-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-09-27 — — US claimed
US-7468243-B2 Nucleotide sequence labelling compoumd four use as tool in genetic engineering AFFYMETRIX, INC. (US) 2008-12-23 — — US claimed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 — — US claimed
US-7282327-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-10-16 — — US claimed
EP-0251760-B1 Rubber composition BRIDGESTONE CORP (JP) 1994-01-26 — — EP claimed
US-5140055-A Improved high speed grip performance BRIDGESTONE CORPORATION (JP) 1992-08-18 — — US claimed
US-4662905-A REACTION PRODUCT OF COPPER SALT AND AN IMIDAZOLE, PYRAZOLE, TRIAZOLE, OR TETRAZOLE Itaru Todoriki, Director of Agency of Industrial Science and Technology (JP) 1987-05-05 — — US claimed
US-20260035749-A1 METHODS AND COMPOSITIONS FOR PREDICTING AND/OR MONITORING CARDIOVASCULAR DISEASE AND TREATMENTS THEREFOR CARDIO DIAGNOSTICS INC (US) 2026-02-05 — — US disclosed
US-12297221-B2 Functionalization and purification of molecules by reversible group exchange ILLUMINA, INC. (US) 2025-05-13 — — US disclosed
US-20240384262-A1 LINKING SEQUENCE READS USING PAIRED CODE TAGS ILLUMINA, INC. 2024-11-21 — — US disclosed
US-20240360513-A1 COMPOSITIONS AND METHODS FOR DETECTING PREDISPOSITION TO CARDIOVASCULAR DISEASE UNIV IOWA RES FOUND (US) 2024-10-31 — — US disclosed
EP-0017908-A1 A method for determining the presence in a sample of an analyte and a kit for use in this method SYVA COMPANY (US) 1980-10-29 — — EP disclosed
EP-0022768-A4 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS. SYVA CO (US) 1980-08-18 — — EP disclosed
WO-1979000882-A1 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS SYVA CO (US) 1979-11-01 — — WO disclosed
US-4011236-A N-(BENZIMIDAZOL-2-YL)ARYLCARBOXAMIDES AS ULTRAVIOLET (UV) LIGHT ABSORBERS MERCK & CO., INC. (US) 1977-03-08 — — US disclosed
US-3933841-A ANTHELMINTICS CIBA-GEIGY CORPORATION (US) 1976-01-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260035749-A1 METHODS AND COMPOSITIONS FOR PREDICTING AND/OR MONITORING CARDIOVASCULAR DISEASE AND TREATMENTS THEREFOR DNMT3A, MECP2, DNMT3L MEN1 3317/4885KMT2A 881/4885AKR1C3 1236/4885
US-12297221-B2 Functionalization and purification of molecules by reversible group exchange PHAX, ALKBH1, JMJD6 MEN1 2992/4885KMT2A 662/4885AKR1C3 3456/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.